spacer
home > ebr > winter 2003 > technical and commercial due diligence in biotech transactions: doing the right things and doing them right
PUBLICATIONS
European Biopharmaceutical Review

Technical and Commercial Due Diligence in Biotech Transactions: Doing the Right Things and Doing them Right

This article argues that conducting due diligence properly to ensure that potential risks and opportunities in biotechnology transactions are fully understood is more important than ever as M&A and technology licensing activities accelerate. There are many ways to go about conducting due diligence, and the factors that determine the right way to proceed are discussed, with the pros and cons set out for taking an in-house approach, versus hiring external consultants. Whatever approach is taken, a due diligence plan is vital, given the often short timescales in which deals need to be closed. Keys to success are ensuring that an independent view is taken and that the right questions are asked, such that the answers truly help to support the investment decision. Due diligence can be an intensive and time-consuming process so the task should not be underestimated or left to the last minute - while it has costs in terms of time or professional fees, cutting corners can turn out to be far more costly.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Simon Shohet, Head of Healthcare and Life Sciences Consulting Team at Cambridge Consultants Ltd

Simon Shohet has been a strategic and commercial advisor and analyst for organisations in the biotechnology and health care industry for over 12 years. Presently, he leads the Healthcare and Life Sciences Consulting team at Cambridge Consultants Ltd (CCL), a sister company of the international management consulting firm Arthur D Little. His team works for European, US and Asia-Pacific-based corporations as well as start-ups and government agencies, helping them to gain competitive advantage through strategic exploitation of life science and biomedical technologies. Before entering consulting he held posts at the Confederation of British Industry (CBI) as a Biotechnology Policy Adviser and London Business School as a Research Fellow in technology economics. He holds a PhD in Microbiology from University College London, and a BSc from the University of Edinburgh. Simon has published numerous papers and articles in management and scientific literature.

spacer
Simon Shohet
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Gerresheimer opens a new plant for the production of pharmaceutical primary plastic packaging in China

Düsseldorf/Changzhou, December 11, 2019 – A new plant for producing plastic pharmaceutical packaging has been set up in the Chinese city of Changzhou to help satisfy the high demand for Gerresheimer’s primary packaging in China in the future. Today the new facility will be officially opened.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement